Back to search

University of Washington

Development of Protein-targeted Aptamers for Cancer Therapeutics

Abstract

dc:description.abstract

Aptamers are single-stranded DNA or RNA molecules capable of recognizing and tightly binding to a variety of targets with high specificity. Treatment of brain and CNS disorders remains the holy grail of drug delivery due to the obstacle imposed by the blood-brain barrier (BBB). Bearing various advantages such as small size, low immunogenicity, and ease of large-scale synthesis at affordable costs, aptamers are an emerging field of novel cancer therapeutics that demonstrate the potential for BBB crossing. Here, we aimed to develop aptamer-based targeting vehicles utilizing the endogenous iron-loading pathway involving the transferrin receptor (TfR, or CD71) and its ligand, transferrin (Tf). We demonstrated our expansive effort in the discovery of Tf binding aptamers via protein-SELEX and the characterization, cross-reactivity, and preliminary data for future applications of a CD71 binding aptamer, tJBA.

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Zhou, Yunshi
Advisor dc:contributor.advisor
  • Pun, Suzie

Subjects

dc:subject × 3

Rights

dc:rights
Statement dc:rights
  • CC BY
Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/1773/45836

Chain of custody

source
Harvested from
University of Washington
Base URL
digital.lib.washington.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Zhou, Yunshi. Development of Protein-targeted Aptamers for Cancer Therapeutics. 2020. http://hdl.handle.net/1773/45836